Voyager Therapeutics (VYGR) Assets Average (2015 - 2026)

Voyager Therapeutics (VYGR) has 12 years of Assets Average data on file, last reported at $235.8 million in Q1 2026.

• For the quarter ending Q1 2026, Assets Average fell 36.81% year-over-year to $235.8 million; the trailing twelve-month figure through Mar 2026 stood at $235.8 million (down 36.81% YoY), and the FY2025 full-year result was $322.7 million, down 13.3% from the prior year.
• Assets Average declined to $235.8 million in Q1 2026, from $270.3 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $452.9 million in Q2 2024 to a low of $170.9 million in Q4 2022.
• A 5-year average of $305.9 million and a median of $305.2 million in 2025 frame the typical range for Assets Average.
• Across the five-year window, Assets Average surged 88.96% in 2023 and sank 36.81% in 2026, its largest moves.
• Tracing VYGR's Assets Average over 5 years: stood at $170.9 million in 2022, then soared by 88.96% to $323.0 million in 2023, then increased by 26.81% to $409.5 million in 2024, then slumped by 34.0% to $270.3 million in 2025, then declined by 12.76% to $235.8 million in 2026.
• Business Quant data shows VYGR's Assets Average at $235.8 million in Q1 2026, $270.3 million in Q4 2025, and $305.2 million in Q3 2025.